Innovation Pharmaceuticals Inc (IPIX)

[slcimmuno]

Is good to see a story about Oral PsO but it isn't Prurisol -- the placebo #s off as you flagged -- also the 26 weeks vs our 16 weeks timeline

Still -- story does show why Orals, like Otezla, can command a substantial part of the market ... 2bn -- pill so much easier to administer

An interview w Dr Forman - about 10.20m in he's asked about an Oral drug trial he's participating in... goes right into talking about JAK inhibitor

http://nationalstrategiespublicrelations.com/project/forman-dermatology-forward-clinical-trials-talks-with-outbreak-news-today-about-psoriasis-clinical-trial-62717/

So there must be a JAK PsO drug, not
Tofacitinib, in testing (Pfizer... failed in PsO due to side effects, but a Go in UC, even if unimpressive #s -- 18% vs 6% active to placebo)

On JAKs
https://www.medpagetoday.com/dermatology/generaldermatology/66485

Forman Mentions "Second Golden Age in PsO Treatments" -- things setting up well if Prurisol delivers the data

Hope we at least match Apremilast and maybe do better -- put a little fear into the Biologics